Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May 5;14(5):e241348.
doi: 10.1136/bcr-2020-241348.

Epstein-Barr virus induced haemophagocytic lymphohistiocytosis

Affiliations
Case Reports

Epstein-Barr virus induced haemophagocytic lymphohistiocytosis

Markie Zimmer et al. BMJ Case Rep. .

Abstract

Haemophagocytic lymphohistiocytosis (HLH) is a rare condition of uncontrolled immune activation as a result of an inherited genetic defect or in response to malignancy, autoimmune disease, rheumatological disease, AIDS infection or post-transplant immunosuppression. Described here is the case of a 19-year-old Caucasian man who presented with complaints of worsening fever, new-onset jaundice and lethargy after failing treatment for suspected infectious mononucleosis. Physical examination was significant for fever and splenomegaly while laboratory results revealed transaminitis, cytopaenia, indirect hyperbilirubinaemia and elevated ferritin, raising the likelihood of both autoimmune haemolytic anaemia and HLH. He tested positive for Epstein-Barr virus (EBV), and bone marrow biopsy revealed hypercellular marrow with haemophagocytosis and no evidence of malignancy. High dose steroids were initiated with significant improvement in haemoglobin, resulting in a final diagnosis of HLH secondary to acute EBV infection. The patient was discharged on continued high-dose prednisone with planned taper and consideration of outpatient rituximab therapy for 4 weeks. High clinical suspicion and prompt evaluation were critical to early treatment and decreased morbidity.

Keywords: haematology (drugs and medicines); haematology (incl blood transfusion); immunology; infections; malignant disease and immunosuppression.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
H&E-stained bone marrow aspirate of the case patient, showing hypercellular marrow with haemophagocytosis.

References

    1. Weaver LK, Behrens EM. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol 2014;26:562–9. 10.1097/BOR.0000000000000093 - DOI - PMC - PubMed
    1. George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med 2014;5:69–86. 10.2147/JBM.S46255 - DOI - PMC - PubMed
    1. Allen CE, McClain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program 2015;2015:177–82. 10.1182/asheducation-2015.1.177 - DOI - PubMed
    1. Wang H, Xiong L, Tang W, et al. . A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions. Oncotarget 2017;8:59977–85. 10.18632/oncotarget.19230 - DOI - PMC - PubMed
    1. Jordan MB, Allen CE, Weitzman S, et al. . How I treat hemophagocytic lymphohistiocytosis. Blood 2011;118:4041–52. 10.1182/blood-2011-03-278127 - DOI - PMC - PubMed

Publication types

MeSH terms